A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
National Institutes of Health Clinical Center (CC)
Genmab
Coherus Oncology, Inc.
Revolution Medicines, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Roswell Park Cancer Institute
Pfizer